Q-omics provides the consensus-scored RBMXP3 profile across patient tissues and cancer cell-line models. RBMXP3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBMXP3 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RBMXP3 RNA expression shows 8,039 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where RBMXP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXP3 survival associations across molecular data types. RBMXP3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXP3 RNA expression–survival associations across cancer types. High RBMXP3 expression shows unfavorable associations in ACC, MESO, LIHC, STAD and KIRP, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBMXP3 RNA expression.
This table summarizes RBMXP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBMXP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXP3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, CHOL, BRCA and KIRC. The COAD box plot shows higher RBMXP3 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p < 0.001).
This table shows molecular features associated with RBMXP3 in patient tissues and cancer cell lines. In patient samples, RBMXP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
